Kristin Muhlner is the founder of Affect. Affect has raised $26M in total funding. Latest round: Series A. Backed by ARTIS Ventures, AlleyCorp, CityLight.
Kristin Muhlner is the Co-Founder and CEO of Affect Therapeutics, a company founded in 2020. Affect Therapeutics focuses on reimagining addiction treatment for the digital age and addressing substance use disorder. She led the company to secure a $16 million Series A round in July 2023, bringing the total funding to approximately $26 million.
Full founder directory · Investor directory · Company funding database · Fundraising library